Brodie / Gillette Drugs and Enzymes

Proceedings of The Second International Pharmacological Meeting, Vol. 4
1. Auflage 2013
ISBN: 978-1-4832-2351-3
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 516 Seiten, Web PDF

Second International Pharmacological Meeting, Volume 4: Drugs and Enzymes is a collection of papers presented at the Second International Pharmacological Meeting on August 20-23, 1963. This volume is organized into two sections encompassing 41 chapters. The first section discusses the relationship between biochemical effects of drugs in vitro and their pharmacological effect in vivo. This section specifically examines the correlation between the action of substances on isolated smooth muscle and on the central nervous system, as well as the behavior of a centrally-acting drug and enzyme in the ion movement in the system. The second section surveys the biochemical mechanisms of drug toxicity. Considerable chapters in this section are devoted to the effect of drug toxicity, such as altered drug metabolism, enzyme induction, morphological changes, hepatic effects, and photosensitivity. This book will prove useful to pharmacologists, neurologists, biochemists, and researchers who are interested the fields of drugs and drug toxicity.

Autoren/Hrsg.

Brodie, Bernard B.

Gillette, James R.

Inhaltsverzeichnis

1;Front Cover;1
2;Drugs and Enzymes;4
3;Copyright Page;5
4;Table of Contents;6
5;LIST OF AUTHORS;10
6;INTRODUCTION;14
7;PART 1: RELATIONSHIP BETWEEN BIOCHEMICAL EFFECTS OF DRUGS IN VITRO AND THEIR PHARMACOLOGICAL EFFECT IN VIVO;20
7.1;Chapter 1. Reversible Binding as a Complication in Relating the in vitro Effect of Drugs to their in vivo Activity;22
7.1.1;DIFFICULTIES IN DETERMINING DRUG LEVELS IN VIVO;23
7.1.2;THEORETICAL ASPECTS OF REVERSIBLE BINDING OF DRUGS TO TISSUES;25
7.1.3;THE EFFECT OF BINDING ON THE APPARENT ACTIVITY OF DRUGS;30
7.1.4;DISCUSSION;34
7.1.5;REFERENCES;34
7.1.6;DISCUSSION;35
7.2;Chapter 2. Correlations between the Action of Substances on Isolated Smooth Muscle and on the Central Nervous System;36
7.2.1;ACETYLCHOLINE;36
7.2.2;CATECHOLAMINES;38
7.2.3;5-HYDROXYTRYPTAMINE;40
7.2.4;REFERENCES;42
7.3;Chapter 3. Drugs and Enzymes of Ion Movement in the Central Nervous System;44
7.3.1;ACTIONS ON ELECTRICAL CHARACTERISTICS OF CEREBRAL TISSUES;44
7.3.2;ACTIONS ON ION MOVEMENTS OF CEREBRAL TISSUES;46
7.3.3;ACTIONS AT SUBCELLULAR AND ENZYMIC SYSTEMS;47
7.3.4;REFERENCES;51
7.4;Chapter 4. Metabolism, Activity and Some Effects of Drugs in Mammalian Non-myelinated Nerve Fibers;54
7.4.1;REFERENCES;66
7.5;Chapter 5. Neurophysiological and Biochemical Correlationsin Isolated Nerve Cell Preparations at Rest and during Impulse Activity;68
7.6;Chapter 6. Effect of Digitalis on Membrane Adenosine Triphosphatase of Cardiac Muscle;78
7.6.1;INTRODUCTION;78
7.6.2;RESULTS AND DISCUSSION;79
7.6.3;CLOSING REMARKS;96
7.6.4;REFERENCES;96
7.6.5;DISCUSSION;99
7.6.6;REFERENCES;100
7.7;Chapter 7. Discussion to paper by K. Repke;102
7.7.1;REFERENCES;106
7.8;Chapter 8. In vivo Factors Influencing the Efficacy of Chelating Compounds as Therapeutic Agents for Metal Toxicity;108
7.8.1;MOBILIZATION OF METALS BY CHELATING AGENTS;108
7.8.2;INTRODUCTION;108
7.8.3;CHEMISTRY OF CHELATES;110
7.8.4;TISSUE METAL BINDING AGENTS – THE SOFT TISSUES;115
7.8.5;TISSUE METAL BINDING SYSTEMS – THE SKELETON;117
7.8.6;CATION CONTENT OF TISSUES AND BODY FLUIDS;118
7.8.7;ENVIRONMENTAL CHARACTERISTICS OF METAL BINDING SITES;118
7.8.8;METABOLIC CHARACTERISTICS OF THE CHELATING AGENT;119
7.8.9;REFERENCES;122
7.8.10;DISCUSSION;123
7.9;Chapter 9. Effets metaboliques de quel ques radio-protecteurs;124
7.9.1;ABRÉVIATIONS UTILISÉES;124
7.9.2;INTRODUCTION;124
7.9.3;RADIO-PROTECTION PAR HYPOXIE;125
7.9.4;RADIO-PROTECTION PAR LES THIOLS ET DISULFURES;130
7.9.5;RADIO-PROTECTION ET MÉTABOLISME ÉNERGETIQUE;144
7.9.6;CONCLUSIONS;148
7.9.7;SUMMARY;150
7.9.8;TRAVAUX CONSULTÉS;151
7.9.9;DISCUSSION;156
7.10;Chapter 10. A Contribution to the Effects of Protective Drugs;158
7.10.1;ACKNOWLEDGMENTS;161
7.10.2;REFERENCES;161
7.10.3;DISCUSSION;161
7.11;Chapter 11. Carbonic Anhydrase Inhibitors;162
7.11.1;REFERENCES;166
7.11.2;DISCUSSION;166
7.12;Chapter 12. The Kinetics of Carbonic Anhydrase and its Inhibition in vivo;168
7.12.1;I. REACTION RATES;170
7.12.2;II. INHIBITION KINETICS, APPLIED IN VIVO;173
7.12.3;III. SULFONAMIDE CHLORURETICS AND CARBONIC ANHYDRASE;183
7.12.4;REFERENCES;185
7.13;Chapter 13. Comparison by Direct Measurement of Sulfonamide Carbonic Anhydrase Inhibition in Whole Cells and in Enzyme Solutions;188
7.13.1;I. MATERIAL AND METHODS;188
7.13.2;II. RESULTS AND DISCUSSION;193
7.13.3;REFERENCES;199
7.14;Chapter 14. Monoamine Oxidase Inhibitors;200
7.14.1;REFERENCES;209
7.15;Chapter 15. Discussion to paper by S. Spector;210
7.15.1;REFERENCES;212
7.16;Chapter 16. Enzymes as Therapeutic Agents;214
7.16.1;REFERENCES;220
7.17;Chapter 17. Modifiers of Adrenocortical Function;222
7.17.1;ACKNOWLEDGEMENT;235
7.17.2;REFERENCES;236
7.18;Chapter 18. Modifiers of Adrenocortical Function— Some Clinical Aspects;238
7.18.1;SUMMARY;244
7.18.2;ACKNOWLEDGMENT;244
7.18.3;REFERENCES;244
7.19;Chapter 19. Xenon Bonding to Proteins — Relationship to Anesthetic Action;246
7.19.1;REFERENCES;250
7.20;Chapter 20. Discussion to paper by R. M. Featherstone;252
7.20.1;REFERENCES;254
8;PART 2: BIOCHEMICAL MECHANISMS OF DRUG TOXICITY;256
8.1;Chapter 21. Individual Variation in Drug Metabolism as Cause of Drug Toxicity;258
8.1.1;REFERENCES;267
8.1.2;DISCUSSION;268
8.2;Chapter 22. Discussion to paper by W. Kalow;270
8.2.1;REFERENCES;273
8.3;Chapter 23. Impairment of Drug Metabolism in Drug Toxicity;274
8.3.1;PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS AFFECTING DRUG METABOLISM;275
8.3.2;RELATIONSHIP BETWEEN HEPATIC GLYCOGEN AND MICROSOMAL DRUG METABOLISM;276
8.3.3;SOME UNUSUAL STIMULATORS OF DRUG-METABOLIZING ENZYME ACTIVITY;279
8.3.4;RELATIONSHIPS BETWEEN HEPATIC ULTRASTRUCTURE AND MICROSOMAL DRUG METABOLISM;282
8.3.5;SUMMARY;287
8.3.6;ACKNOWLEDGMENTS;288
8.3.7;REFERENCES;288
8.4;Chapter 24. Enzyme Induction and Drug Toxicity;290
8.4.1;EFFECT OF ENZYME INDUCTION ON THE ACUTE TOXICITY OF DRUGS;294
8.4.2;ENZYME INDUCTION IN CHRONIC TOXICITY STUDIES;295
8.4.3;INDUCTION OF DRUG-METABOLIZING ENZYMES IN NON-HEPATIC TISSUES;298
8.4.4;SPECIFICITY OF POLYCYCLIC HYDROCARBONS AND DRUGS AS ENZYME INDUCERS;299
8.4.5;MECHANISM OF THE STIMULATORY EFFECT OF POLYCYCLIC HYDROCARBONS AND DRUGS ON MICROSOMAL ENZYME ACTIVITY;300
8.4.6;STIMULATORY EFFECT OF DRUGS ON THE METABOLISM OF NORMAL BODY CONSTITUENTS;305
8.4.7;SUMMARY;306
8.4.8;ACKNOWLEDGEMENTS;307
8.4.9;REFERENCES;307
8.5;Chapter 25. Morphological Changes in the Endoplasmic Reticulum of the Liver Cells with Enzyme Induction after Pretreatment with Several Drugs;312
8.5.1;REFERENCES;320
8.6;Chapter 26. Biochemical Factors in the Formation of Active and Toxic Metabolic Products;322
8.6.1;THE FORMATION OF TOXIC AND ACTIVE PRODUCTS BY BIOCHEMICAL TRANSFORMATION;322
8.6.2;THE FORMATION OF ACTIVE AND TOXIC METABOLITES BY MICROSOMAL ENZYMES;326
8.6.3;TISSUE STORAGE AND THE ACTIVITY AND TOXICITY OF DRUGS;333
8.6.4;REFERENCES;334
8.7;Chapter 27. Discussion to paper by J. Axelrod;338
8.7.1;REFERENCES;342
8.8;Chapter 28. Biochemistry of Rodenticides;344
8.8.1;BIOCHEMICAL ASPECTS;345
8.8.2;ARYLTHIOUREAS AS RODENTICIDES;350
8.8.3;REFERENCES;353
8.9;Chapter 29. Mechanisms of Drug-induced Carcinogenesis;356
8.9.1;REFERENCES;362
8.10;Chapter 30. Biochemical Factors in Carbon Tetrachloride Toxicity;364
8.10.1;REFERENCES;373
8.11;Chapter 31. Investigations on the Early Effects of CCI4 on Lipid Transport;376
8.11.1;REFERENCES;382
8.12;Chapter 32. Hepatic Lipid Transport and Lipoprotein-protein Synthesis: Effects of CCI4 Intoxication;384
8.12.1;REFERENCES;393
8.13;Chapter 33. Cumulative Effects of Reserpine on the Pituitary-adrenocortical and Sympathetic Nervous System;394
8.13.1;REFERENCES;404
8.13.2;DISCUSSION;405
8.14;Chapter 34. Inactivation of SH-Enzymes in Drug-induced Hemolysis;406
8.14.1;REFERENCES;411
8.15;Chapter 35. Discussion to paper by S. Rapoport and D. Scheuch;412
8.15.1;REFERENZEN;416
8.16;Chapter 36. Hepatotoxic Drugs Causing Porphyria in Man and Animals;418
8.16.1;TOXIC PORPHYRIA IN ANIMALS;420
8.16.2;TOXIC PORPHYRIA IN MAN;427
8.16.3;REFERENCES;429
8.17;Chapter 37. Photosensitivity to Drugs;432
8.17.1;ACKNOWLEDGMENTS;449
8.17.2;REFERENCES;449
8.17.3;DISCUSSION;454
8.18;Chapter 38. Specificity in Delayed-type Reactions to Simple Chemicals;456
8.18.1;METHODS;457
8.18.2;RESULTS;458
8.18.3;DISCUSSION;463
8.18.4;SUMMARY;464
8.18.5;REFERENCES;465
8.19;Chapter 39. Metabolische Studien mit Thalidomid und seinen Stoffwechselprodukten;466
8.19.1;DIE FRAGE DER HYDROXYLIERTEN METABOLITEN VON THALIDO;468
8.19.2;DER MECHANISMUS DER HYDROLYTISCHEN SPALTUNG DES THALIDOMID-MOLEKÜLS;469
8.19.3;DIE BIOLOGISCHEN EIGENSCHAFTEN DER METABOLITEN VON THALIDOMID;471
8.19.4;SUMMARY;473
8.19.5;REFERENZEN;474
8.19.6;DISCUSSION;474
8.20;Chapter 40. Discussion to paper by J. W . Faigle et al;476
8.20.1;REFERENCES;480
8.20.2;DISCUSSION;480
8.21;Chapter 41. Chloroquine Toxicity;482
8.21.1;MATERIALS AND METHODS;484
8.21.2;CLINICAL STUDIES;485
8.21.3;ASSAY OF CHLOROQUINE AND METABOLITE;485
8.21.4;RESULTS;487
8.21.5;DISCUSSION;495
8.21.6;SUMMARY;500
8.21.7;REFERENCES;500
9;INDEX;504